Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification

David S. Priemer, Rodolfo Montironi, Lisha Wang, Sean R. Williamson, Antonio Lopez-Beltran, Liang Cheng

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Neuroendocrine neoplasms of the prostate represent a multifarious group of tumors that exist both in pure forms and associated with prostatic adenocarcinoma. Morphologically, neuroendocrine cells in prostate neoplasms can range from being indistinguishable from surrounding prostate adenocarcinoma cells to having high-grade neuroendocrine appearances similar to neuroendocrine malignancies of other organs. On the molecular level, neuroendocrine malignancies arising in the setting of prostate adenocarcinoma have been the subject of a large amount of recent research, most of which has supported the conclusion that neuroendocrine malignancy within the prostate develops as a transdifferentiation from prostate adenocarcinoma. There has not, however, been substantial investigation into rare, pure neuroendocrine malignancies and the possibility that these tumors may have a different cell of origin and molecular genesis. Here, we discuss the morphologic spectrum of malignant neuroendocrine prostate neoplasms and review the most recent molecular data on the subject of malignant neuroendocrine differentiation in prostatic adenocarcinoma. In reflection of the most recent data, we also discuss diagnostic classification of prostate neuroendocrine tumors with reference to the 2016 World Health Organization (WHO) classification. We discuss the reporting of these tumors, placing emphasis on the differentiation between pure and mixed neuroendocrine malignancies so that, in the least, they can be easily identified for the purposes of future clinical and laboratory-based investigation. Finally, we suggest a designation for an unclassifiable (or not otherwise specified) high-grade neuroendocrine prostate malignancy whose features do not easily place it into one of the WHO diagnostic entities.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalEndocrine Pathology
DOIs
StateAccepted/In press - Feb 17 2016

Fingerprint

Neuroendocrine Tumors
Prostate
Adenocarcinoma
Neoplasms
Prostatic Neoplasms
Neuroendocrine Cells

Keywords

  • Castration-resistant prostate cancer (CRPC)
  • Large cell neuroendocrine carcinoma
  • Molecular cytogenetics
  • Neuroendocrine differentiation
  • Prostate cancer
  • Small cell carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Neuroendocrine Tumors of the Prostate : Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification. / Priemer, David S.; Montironi, Rodolfo; Wang, Lisha; Williamson, Sean R.; Lopez-Beltran, Antonio; Cheng, Liang.

In: Endocrine Pathology, 17.02.2016, p. 1-13.

Research output: Contribution to journalArticle

Priemer, David S. ; Montironi, Rodolfo ; Wang, Lisha ; Williamson, Sean R. ; Lopez-Beltran, Antonio ; Cheng, Liang. / Neuroendocrine Tumors of the Prostate : Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification. In: Endocrine Pathology. 2016 ; pp. 1-13.
@article{c918aee570a74c22aa624da820001dfc,
title = "Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification",
abstract = "Neuroendocrine neoplasms of the prostate represent a multifarious group of tumors that exist both in pure forms and associated with prostatic adenocarcinoma. Morphologically, neuroendocrine cells in prostate neoplasms can range from being indistinguishable from surrounding prostate adenocarcinoma cells to having high-grade neuroendocrine appearances similar to neuroendocrine malignancies of other organs. On the molecular level, neuroendocrine malignancies arising in the setting of prostate adenocarcinoma have been the subject of a large amount of recent research, most of which has supported the conclusion that neuroendocrine malignancy within the prostate develops as a transdifferentiation from prostate adenocarcinoma. There has not, however, been substantial investigation into rare, pure neuroendocrine malignancies and the possibility that these tumors may have a different cell of origin and molecular genesis. Here, we discuss the morphologic spectrum of malignant neuroendocrine prostate neoplasms and review the most recent molecular data on the subject of malignant neuroendocrine differentiation in prostatic adenocarcinoma. In reflection of the most recent data, we also discuss diagnostic classification of prostate neuroendocrine tumors with reference to the 2016 World Health Organization (WHO) classification. We discuss the reporting of these tumors, placing emphasis on the differentiation between pure and mixed neuroendocrine malignancies so that, in the least, they can be easily identified for the purposes of future clinical and laboratory-based investigation. Finally, we suggest a designation for an unclassifiable (or not otherwise specified) high-grade neuroendocrine prostate malignancy whose features do not easily place it into one of the WHO diagnostic entities.",
keywords = "Castration-resistant prostate cancer (CRPC), Large cell neuroendocrine carcinoma, Molecular cytogenetics, Neuroendocrine differentiation, Prostate cancer, Small cell carcinoma",
author = "Priemer, {David S.} and Rodolfo Montironi and Lisha Wang and Williamson, {Sean R.} and Antonio Lopez-Beltran and Liang Cheng",
year = "2016",
month = "2",
day = "17",
doi = "10.1007/s12022-016-9421-z",
language = "English (US)",
pages = "1--13",
journal = "Endocrine Pathology",
issn = "1046-3976",
publisher = "Humana Press",

}

TY - JOUR

T1 - Neuroendocrine Tumors of the Prostate

T2 - Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification

AU - Priemer, David S.

AU - Montironi, Rodolfo

AU - Wang, Lisha

AU - Williamson, Sean R.

AU - Lopez-Beltran, Antonio

AU - Cheng, Liang

PY - 2016/2/17

Y1 - 2016/2/17

N2 - Neuroendocrine neoplasms of the prostate represent a multifarious group of tumors that exist both in pure forms and associated with prostatic adenocarcinoma. Morphologically, neuroendocrine cells in prostate neoplasms can range from being indistinguishable from surrounding prostate adenocarcinoma cells to having high-grade neuroendocrine appearances similar to neuroendocrine malignancies of other organs. On the molecular level, neuroendocrine malignancies arising in the setting of prostate adenocarcinoma have been the subject of a large amount of recent research, most of which has supported the conclusion that neuroendocrine malignancy within the prostate develops as a transdifferentiation from prostate adenocarcinoma. There has not, however, been substantial investigation into rare, pure neuroendocrine malignancies and the possibility that these tumors may have a different cell of origin and molecular genesis. Here, we discuss the morphologic spectrum of malignant neuroendocrine prostate neoplasms and review the most recent molecular data on the subject of malignant neuroendocrine differentiation in prostatic adenocarcinoma. In reflection of the most recent data, we also discuss diagnostic classification of prostate neuroendocrine tumors with reference to the 2016 World Health Organization (WHO) classification. We discuss the reporting of these tumors, placing emphasis on the differentiation between pure and mixed neuroendocrine malignancies so that, in the least, they can be easily identified for the purposes of future clinical and laboratory-based investigation. Finally, we suggest a designation for an unclassifiable (or not otherwise specified) high-grade neuroendocrine prostate malignancy whose features do not easily place it into one of the WHO diagnostic entities.

AB - Neuroendocrine neoplasms of the prostate represent a multifarious group of tumors that exist both in pure forms and associated with prostatic adenocarcinoma. Morphologically, neuroendocrine cells in prostate neoplasms can range from being indistinguishable from surrounding prostate adenocarcinoma cells to having high-grade neuroendocrine appearances similar to neuroendocrine malignancies of other organs. On the molecular level, neuroendocrine malignancies arising in the setting of prostate adenocarcinoma have been the subject of a large amount of recent research, most of which has supported the conclusion that neuroendocrine malignancy within the prostate develops as a transdifferentiation from prostate adenocarcinoma. There has not, however, been substantial investigation into rare, pure neuroendocrine malignancies and the possibility that these tumors may have a different cell of origin and molecular genesis. Here, we discuss the morphologic spectrum of malignant neuroendocrine prostate neoplasms and review the most recent molecular data on the subject of malignant neuroendocrine differentiation in prostatic adenocarcinoma. In reflection of the most recent data, we also discuss diagnostic classification of prostate neuroendocrine tumors with reference to the 2016 World Health Organization (WHO) classification. We discuss the reporting of these tumors, placing emphasis on the differentiation between pure and mixed neuroendocrine malignancies so that, in the least, they can be easily identified for the purposes of future clinical and laboratory-based investigation. Finally, we suggest a designation for an unclassifiable (or not otherwise specified) high-grade neuroendocrine prostate malignancy whose features do not easily place it into one of the WHO diagnostic entities.

KW - Castration-resistant prostate cancer (CRPC)

KW - Large cell neuroendocrine carcinoma

KW - Molecular cytogenetics

KW - Neuroendocrine differentiation

KW - Prostate cancer

KW - Small cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84958761514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958761514&partnerID=8YFLogxK

U2 - 10.1007/s12022-016-9421-z

DO - 10.1007/s12022-016-9421-z

M3 - Article

C2 - 26885643

AN - SCOPUS:84958761514

SP - 1

EP - 13

JO - Endocrine Pathology

JF - Endocrine Pathology

SN - 1046-3976

ER -